Evidence map›Paper›PMID 35142962›Full record

ArticleInternational journal of clinical oncology2022

Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.

Ryotaro Tomida, Makito Miyake, Ryoei Minato, Yuichiro Sawada, Masafumi Matsumura, Kota Iida, Shunta Hori, Shinji Fukui, Chikara Ohyama, Hideaki Miyake and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Ryotaro TomidaUrology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan.ORCID http://orcid.org/0000-0002-2518-0197
Makito MiyakeDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp.ORCID http://orcid.org/0000-0001-9503-7356
Ryoei MinatoUrology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan.
Yuichiro SawadaUrology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan.
Masafumi MatsumuraUrology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan.
Kota IidaDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Shunta HoriDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Shinji FukuiDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hideaki MiyakeDepartment of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Fumiya HongoDepartment of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Rikiya TaokaDepartment of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Takashi KobayashiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takahiro KojimaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yoshiyuki MatsuiDepartment of Urology, National Cancer Center Hospital, Tokyo, Japan.
Naotaka NishiyamaDepartment of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan.
Hiroshi KitamuraDepartment of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Kiyohide FujimotoDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Katsuyoshi HashineUrology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan.
Japanese Urological Oncology Group
Nara Medical University · JPShikoku Cancer Center · JPUniversity of Toyama · JPUniversity of Tsukuba · JPHamamatsu University School of Medicine · JPHirosaki University · JPKagawa University · JPKyoto Prefectural University of Medicine · JPKyoto University · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study investigated the clinical impact of carcinoma in situ (CIS) in intravesical Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle-invasive bladder cancer (NMIBC).

methodsThis study retrospectively evaluated 3035 patients who were diagnosed with NMIBC and treated by intravesical BCG therapy between 2000 and 2019 at 31 institutions. Patients were divided into six groups according to the presence of CIS as follows: low-grade Ta without concomitant CIS, high-grade Ta without concomitant CIS, high-grade Ta with concomitant CIS, high-grade T1 without concomitant CIS, high-grade T1 with concomitant CIS, and pure CIS (without any papillary lesion). The endpoints were recurrence- and progression-free survival after the initiation of BCG therapy. We analyzed to identify factors associated with recurrence and progression.

resultsAt a median follow-up of 44.4 months, recurrence and progression were observed in 955 (31.5%) and 316 (10.4%) patients, respectively. Comparison of six groups using univariate and multivariate analysis showed no significant association of CIS. However, CIS in the prostatic urethra was an independent factors associated with progression.

conclusionConcomitant CIS did not show a significant impact in the analysis of Ta and T1 tumors which were treated using intravesical BCG. Concomitant CIS in the prostatic urethra was associated with high risk of progression. Alternative treatment approaches such as radical cystectomy should be considered for patients with NMIBC who have a risk of progression.

Indexed as

Carcinoma in SituUrinary Bladder NeoplasmsAdjuvants, ImmunologicAdministration, IntravesicalBCG VaccineCystectomyFemaleHumansMaleNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesAdjuvants, ImmunologicBCG VaccineBacillus Calmette-GuérinBladder cancerCarcinoma in situNon-muscle-invasive bladder cancer

Identifiers

PMID35142962
OpenAlexW4211117001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.